Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611966 | 1.00 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7610514 | 0.99 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7617382 | 0.95 | CHRM1 (0.71) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL29510370 | 0.91 | CHRM1 (0.64) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7609678 | 0.91 | CHRM1 (0.69) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7611132 | 0.89 | CHRM1 (0.74) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7610906 | 0.89 | CHRM1 (0.74) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL30131204 | 0.87 | CHRM1 (0.65) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Pyridine SCHEMBL27453932 | 0.87 | CHRM1 (0.65) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7620716 | 0.86 | CHRM1 (0.78) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-115974863-B | Malate and A crystal forms of taking-up nonimeilin derivative, preparation method and application thereof | 南京迈诺威医药科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | TERRAN BIOSCIENCES INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023061372-A1 | MALATE SALT OF XANOMELINE DERIVATIVE, CRYSTALLINE FORM A, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京迈诺威医药科技有限公司 | 2023-04-20 | — | — | WO | disclosed |
| CN-115974863-A | Malate of xanomeline derivative, crystal form A, preparation method of malate, and application of crystal form A | 南京迈诺威医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-0384288-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1995-05-24 | — | — | EP | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
| US-5328925-A | Alzheimer*s disease | NOVO NORDISK A/S (DK) | 1994-07-12 | — | — | US | disclosed |
| US-5284859-A | Analgesics, Alzheimer's disease | NOVO NORDISK A/S (DK) | 1994-02-08 | — | — | US | disclosed |
| US-5264444-A | Cognition activators | NOVO NORDISK A/S (DK) | 1993-11-23 | — | — | US | disclosed |
| US-5260311-A | Cognition activators, analgesics for sever pain, glaucoma treatment | NOVO NORDISK A/S (DK) | 1993-11-09 | — | — | US | disclosed |
| US-5043345-A | Cognition activators; alzheimer's disease | NOVO NORDISK A/S (DK) | 1991-08-27 | — | — | US | disclosed |
| US-5041455-A | Stimulants of cognitive function in mammals | NOVO NORDISK A/S (DK) | 1991-08-20 | — | — | US | disclosed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | CHRM1, RXFP3, NPY5R | CHRM1 1/4885CHRM2 8/4885CHRM4 27/4885 |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | HTR5A, HTR3A, HTR3B | CHRM1 227/4885CHRM2 314/4885CHRM4 148/4885 |
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | CHRM1 227/4885CHRM2 314/4885CHRM4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.